Mahmoud A. Senousy
Egyptian Chinese University, Egypt
Title: Cromolyn chitosan nanoparticles modulate the DNA methylation of RASSF1A and p16 tumor suppressor genes and lessen DNMT1 and METTL3 expression in MCF-7 breast cancer cell line
Biography
Biography: Mahmoud A. Senousy
Abstract
Recently, the use of nanotechnology has boosted the prevention, diagnosis and treatment of breast cancer (BC) through enhancing the effectiveness of chemotherapeutic drugs and decreasing its toxicity as they can target tumor cells with high specificity. However; developing epigenetic drugs with nanoformulation for BC remains a novel therapeutic approach. Cromolyn is a mast cell stabilizer emerging as an anticancer drug; its encapsulation in chitosan nanoparticles (CSNPs) improves its effect and bioavailability. Howbeit, its effect on DNA and RNA methylation machineries has not been previously investigated. The possible anticancer effect of cromolyn CSNPs and its potential as an epigenetic drug was investigated in vitro using MCF-7 human BC cell line. Cromolyn CSNPs showed prominent anticancer effect in MCF-7 cells by reducing the cell viability percent and enhancing DNA damage in the comet assay demonstrating its apoptotic actions. Mechanistically, cromolyn CSNPs influenced potential epigenetic processes.